PhotoPharmics careers

Over 10 million people worldwide live with Parkinson’s disease (PD). While many are stably treated with dopaminergic drugs, most PD patients continue to experience difficulties with motor symptoms (e.g., gait, balance, resting tremor) and non-motor symptoms (e.g., sleep disorders, fatigue, and mood and cognitive problems). Impaired function and reduced quality of life often prevents those living with PD from working, exercising, socializing, and doing the things they want to do.

Our novel therapy called Spectramax has been shown to improve the non-motor symptoms of Parkinson’s disease and improve quality of life. Bolstered by recent discoveries and our own clinical trials, we’re moving closer to a breakthrough.

We invite you to join us in our efforts to improve the quality of life of PD patients and help them be their best.